Published in Curr HIV/AIDS Rep on June 01, 2005
Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med (2002) 9.70
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med (2009) 4.54
Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis (2005) 3.93
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (2008) 3.14
Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease. J Infect Dis (2004) 2.91
Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis (2003) 2.54
Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis (2011) 2.34
Human immunodeficiency virus type 1 (HIV-1) diversity at time of infection is not restricted to certain risk groups or specific HIV-1 subtypes. J Virol (2004) 2.33
The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis (2011) 2.26
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis (2011) 2.12
Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. Virology (2006) 2.07
Incidence of HIV superinfection following primary infection. JAMA (2004) 1.92
Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J Virol (2010) 1.80
Human immunodeficiency virus type 1 clade B superinfection: evidence for differential immune containment of distinct clade B strains. J Virol (2005) 1.77
A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients. J Acquir Immune Defic Syndr (2007) 1.76
HLA-B63 presents HLA-B57/B58-restricted cytotoxic T-lymphocyte epitopes and is associated with low human immunodeficiency virus load. J Virol (2005) 1.76
Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med (2014) 1.75
Transmission behaviors of recently HIV-infected men who have sex with men. J Acquir Immune Defic Syndr (2006) 1.73
Unprotected anal intercourse and substance use among men who have sex with men with recent HIV infection. J Acquir Immune Defic Syndr (2006) 1.66
Diagnostic discordance for hepatitis C virus infection in hemodialysis patients. Am J Kidney Dis (2005) 1.60
Behaviors of recently HIV-infected men who have sex with men in the year postdiagnosis: effects of drug use and partner types. J Acquir Immune Defic Syndr (2011) 1.54
Shedding of HIV and human herpesviruses in the semen of effectively treated HIV-1-infected men who have sex with men. Clin Infect Dis (2013) 1.53
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenet Genomics (2012) 1.52
Asymptomatic sexually transmitted infections in HIV-infected men who have sex with men: prevalence, incidence, predictors, and screening strategies. AIDS Patient Care STDS (2008) 1.45
Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis (2011) 1.40
Cognitive-behavioral intervention to enhance adherence to antiretroviral therapy: a randomized controlled trial (CCTG 578). AIDS (2006) 1.37
Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS (2012) 1.34
Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol (2007) 1.26
Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. J Infect Dis (2013) 1.26
Molecular analysis of HIV strains from a cluster of worker infections in the adult film industry, Los Angeles 2004. AIDS (2006) 1.25
Antiretroviral drug resistance and risk behavior among recently HIV-infected men who have sex with men. J Acquir Immune Defic Syndr (2008) 1.14
Barriers and unmet need for supportive services for HIV patients in care in Los Angeles County, California. AIDS Patient Care STDS (2011) 1.08
Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202. J Acquir Immune Defic Syndr (2014) 1.06
Increasing CTL targeting of conserved sequences during early HIV-1 infection is correlated to decreasing viremia. AIDS Res Hum Retroviruses (2010) 1.02
Disrupted cerebral metabolite levels and lower nadir CD4 + counts are linked to brain volume deficits in 210 HIV-infected patients on stable treatment. Neuroimage Clin (2013) 1.01
Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202. J Infect Dis (2012) 0.99
Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients. AIDS (2010) 0.98
Unprotected anal intercourse and substance use before and after HIV diagnosis among recently HIV-infected men who have sex with men. Sex Transm Dis (2007) 0.98
Characteristics of recently HIV-infected men who use the Internet to find male sex partners and sexual practices with those partners. J Acquir Immune Defic Syndr (2006) 0.97
HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status. J Infect Dis (2012) 0.96
Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics (2014) 0.95
Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2004) 0.94
Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection. J Virol (2004) 0.93
Virologic correlates of anti-CMV IgG levels in HIV-1-infected men. J Infect Dis (2013) 0.93
Platelet count is associated with plasma HIV type 1 RNA and disease progression. AIDS Res Hum Retroviruses (2007) 0.91
Longitudinal analysis of CD8 T-cell responses to HIV and hepatitis C virus in a cohort of co-infected haemophiliacs. AIDS (2005) 0.90
Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance. AIDS (2008) 0.89
Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine. Clin Infect Dis (2013) 0.89
Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease. Antivir Ther (2012) 0.88
Regional areas and widths of the midsagittal corpus callosum among HIV-infected patients on stable antiretroviral therapies. J Neurovirol (2011) 0.88
Plasma and Cerebrospinal Fluid Biomarkers Predict Cerebral Injury in HIV-Infected Individuals on Stable Combination Antiretroviral Therapy. J Acquir Immune Defic Syndr (2015) 0.87
Hepatitis C virus/HIV coinfection and responses to initial antiretroviral treatment. AIDS (2013) 0.87
Impact of randomized antiretroviral therapy initiation on glucose metabolism. AIDS (2014) 0.86
Primary human immunodeficiency virus type 1 (HIV-1) infection during HIV-1 Gag vaccination. J Virol (2008) 0.86
Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density. AIDS (2013) 0.85
Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine. J Acquir Immune Defic Syndr (2014) 0.84
Limited nucleotide changes in the Rev response element (RRE) during HIV-1 infection alter overall Rev-RRE activity and Rev multimerization. J Virol (2013) 0.84
Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet Genomics (2015) 0.84
Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202. J Infect Dis (2012) 0.83
Distinct cytokine/chemokine network in semen and blood characterize different stages of HIV infection. AIDS (2016) 0.82
Brief Report: Effect of CMV and HIV Transcription on CD57 and PD-1 T-Cell Expression During Suppressive ART. J Acquir Immune Defic Syndr (2016) 0.81
Isolation and characterization of an infectious HIV type 1 molecular clone from a patient with primary infection. AIDS Res Hum Retroviruses (2002) 0.81
Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202. J Antimicrob Chemother (2014) 0.79
Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s. J Acquir Immune Defic Syndr (2015) 0.79
Open-label, randomized, parallel-group controlled clinical trial of massage for treatment of depression in HIV-infected subjects. J Altern Complement Med (2012) 0.78
Hepatitis C infection in dialysis patients: a link to poor clinical outcome? Int Urol Nephrol (2006) 0.78
Short communication: HIV-1 gag genetic variation in a single acutely infected participant defined by high-resolution deep sequencing. AIDS Res Hum Retroviruses (2014) 0.78
Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity. AIDS (2006) 0.78
Newer antiretroviral agents and how to use them. Curr HIV/AIDS Rep (2009) 0.78
Antiretroviral regimens for treatment-experienced patients with HIV-1 infection. Expert Opin Pharmacother (2008) 0.77
Role of GB virus C in HIV-1-infected and hepatitis C virus-infected hemophiliac children and adolescents. J Acquir Immune Defic Syndr (2012) 0.77
A Remotely-Delivered CBT and Contingency Management Therapy for Substance Using People with HIV. AIDS Behav (2015) 0.76
Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics (2015) 0.76
Measuring below the bar: what is it telling us? AIDS (2006) 0.75
Phase I/II trial of the anti-HIV activity of mifepristone in HIV-infected subjects ACTG 5200. J Acquir Immune Defic Syndr (2010) 0.75
Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue. J Acquir Immune Defic Syndr (2016) 0.75
Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics (2017) 0.75
Experience and challenges presented by a multicenter crossover study of combination analgesic therapy for the treatment of painful HIV-associated polyneuropathies. Pain Med (2013) 0.75
Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Ther Drug Monit (2017) 0.75
Antiretroviral rounds. The when, why and how of switching. AIDS Clin Care (2003) 0.75
Newer antiretroviral agents and how to use them. Curr Infect Dis Rep (2009) 0.75
What's next? Treatment options when the first antiretroviral regimen fails virologically or is not tolerated, Part 2. AIDS Read (2004) 0.75
What's next? Treatment options when the first antiretroviral regimen fails virologically or is not tolerated, Part 1. AIDS Read (2004) 0.75
Antiretroviral rounds. Putting resistance to work. AIDS Clin Care (2004) 0.75
Strategies for initiating combination antiretroviral therapy. AIDS Patient Care STDS (2005) 0.75
A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimens. J Comp Eff Res (2015) 0.75
Novel antiretroviral agents in HIV therapy. Curr Infect Dis Rep (2006) 0.75